← back to search

Emily Han-Chung Hsiue

Howard Hughes Medical Institute · US
Area of research
Radiology, Nuclear Medicine and Imaging · Oncology
Research interest
Research interests include Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, CAR-T cell therapy research, and Advanced Biosensing Techniques and Applications.
h-index
20
citations
2,046
works
84
NIH funding
primary concept
email

Recent publications

Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
Science Translational Medicine 2024cited by 21position: middledoi
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape
eLife 2024cited by 8position: middledoi
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
Nature Communications 2023cited by 25position: middledoi
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Nature 2021cited by 534position: middledoi
Targeting a neoantigen derived from a common <i>TP53</i> mutation
Science 2021cited by 341position: firstdoi
Targeting public neoantigens for cancer immunotherapy
Nature Cancer 2021cited by 176position: middledoi
Bispecific antibodies targeting mutant<i>RAS</i>neoantigens
Science Immunology 2021cited by 166position: middledoi
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes
Journal for ImmunoTherapy of Cancer 2021cited by 120position: middledoi
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses
Journal of Clinical Investigation 2021cited by 92position: middledoi
TCR β chain–directed bispecific antibodies for the treatment of T cell cancers
Science Translational Medicine 2021cited by 55position: middledoi
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
Nature Communications 2021cited by 38position: middledoi
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Nature 2021cited by 13position: middledoi
Author Correction: Targeting public neoantigens for cancer immunotherapy
Nature Cancer 2021cited by 3position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Shibin Zhou · Bloomberg (United States)8 papers (2021–2024)Kenneth W. Kinzler · University of Baltimore8 papers (2021–2024)Drew M. Pardoll · Bloomberg (United States)8 papers (2021–2024)Chetan Bettegowda · Seattle University8 papers (2021–2024)Bert Vogelstein · Clinical Pharmacology of Miami8 papers (2021–2024)Jacqueline Douglass · Howard Hughes Medical Institute7 papers (2021–2024)Sarah R. DiNapoli · Howard Hughes Medical Institute7 papers (2021–2024)Alexander H. Pearlman · Howard Hughes Medical Institute7 papers (2021–2024)Maximilian F. Konig · Howard Hughes Medical Institute7 papers (2021–2024)Brian J. Mog · Howard Hughes Medical Institute7 papers (2021–2024)Sandra B. Gabelli · Johns Hopkins Medicine7 papers (2021–2024)Nickolas Papadopoulos · Ludwig Cancer Research6 papers (2021–2024)Suman Paul · Johns Hopkins University6 papers (2021–2024)Katharine M. Wright · Howard Hughes Medical Institute5 papers (2021–2024)Michael S. Hwang · University of California, San Francisco5 papers (2021–2024)P. Aitana Azurmendi · Howard Hughes Medical Institute4 papers (2021–2024)Michelle S. Miller · The University of Melbourne4 papers (2021–2024)Evangeline Watson · Howard Hughes Medical Institute3 papers (2021–2024)Yana Li · The First Affiliated Hospital, Sun Yat-sen University2 papers (2021–2021) · 2 papers (2021–2021)